MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

219.64 -1.75

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

218.74

Макс.

220.24

Ключевые показатели

By Trading Economics

Доход

2.9M

56M

Продажи

-27M

1B

Прибыль на акцию

2.43

Рентабельность продаж

5.529

Сотрудники

18,700

EBITDA

-23M

198M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+0.88% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

18 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2B

11B

Предыдущая цена открытия

221.39

Предыдущая цена закрытия

219.64

Новостные настроения

By Acuity

50%

50%

142 / 352 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 янв. 2026 г., 18:41 UTC

Отчет

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24 янв. 2026 г., 09:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 янв. 2026 г., 09:20 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

24 янв. 2026 г., 09:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

24 янв. 2026 г., 09:20 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

24 янв. 2026 г., 06:18 UTC

Приобретения, слияния, поглощения

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 янв. 2026 г., 22:30 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 янв. 2026 г., 22:30 UTC

Обсуждения рынка

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 янв. 2026 г., 22:03 UTC

Отчет

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 янв. 2026 г., 21:52 UTC

Отчет
Приобретения, слияния, поглощения

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

23 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

23 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

23 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

23 янв. 2026 г., 21:39 UTC

Отчет

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 янв. 2026 г., 21:15 UTC

Приобретения, слияния, поглощения

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 янв. 2026 г., 21:12 UTC

Отчет

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 янв. 2026 г., 20:31 UTC

Отчет

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 янв. 2026 г., 20:12 UTC

Обсуждения рынка

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 янв. 2026 г., 20:07 UTC

Обсуждения рынка

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 янв. 2026 г., 19:36 UTC

Обсуждения рынка

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 янв. 2026 г., 19:30 UTC

Обсуждения рынка
Отчет

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 янв. 2026 г., 19:18 UTC

Обсуждения рынка

Gold and Silver Step Up to More Records -- Market Talk

23 янв. 2026 г., 19:15 UTC

Отчет

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23 янв. 2026 г., 18:53 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23 янв. 2026 г., 18:21 UTC

Отчет

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23 янв. 2026 г., 18:19 UTC

Обсуждения рынка

Intel Seen as Increasingly Confident on Demand -- Market Talk

23 янв. 2026 г., 17:59 UTC

Отчет

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23 янв. 2026 г., 17:57 UTC

Обсуждения рынка

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23 янв. 2026 г., 17:57 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

0.88% рост

Прогноз на 12 месяцев

Средняя 221.55 USD  0.88%

Максимум 265 USD

Минимум 170 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

13 ratings

9

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

117.16 / 144.77Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

142 / 352Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat